A diagnosis of metastatic kidney cancer can be overwhelming.
When kidney cancer has spread beyond the kidney, the treatment plan is different from that of a cancer confined to the kidney. Surgery may still be useful in selected patients, but removing the kidney is not automatically the first step for every patient with metastatic disease.
The decision depends on:
The goal is not simply to remove the kidney. The goal is to develop the most appropriate overall cancer treatment plan for that individual patient.
Kidney cancer is called metastatic when cancer cells have spread from the kidney to distant sites.
Common sites of metastatic renal cell carcinoma include:
The cancer found at these sites is still kidney cancer. For example, if renal cell carcinoma spreads to the lung, it is called metastatic kidney cancer in the lung, not primary lung cancer.
Metastatic kidney cancer is generally classified as Stage IV disease.
No.
But surgery has to be considered in the context of the entire disease.
Some patients have widespread disease where systemic treatment is the main treatment.
Others may have:
In carefully selected patients, surgery may therefore remain an important part of treatment.
For most patients with newly diagnosed metastatic renal cell carcinoma, systemic treatment plays a central role because cancer cells are present outside the kidney.
Depending on the cancer type, risk group, previous treatment and individual circumstances, systemic treatment may include:
Immune checkpoint inhibitors are used to help the immune system recognise and attack cancer cells.
Targeted medicines act on specific pathways involved in the growth and survival of kidney cancer cells.
Modern treatment frequently uses combinations of immunotherapy and/or targeted therapy depending on the clinical situation.
The exact drug combination should not be chosen simply because it is commonly used. Histology, risk category, previous treatment, organ function, symptoms and other patient-specific factors all matter.
Current treatment options continue to evolve, and clinical trials remain an important part of advanced kidney cancer care.
No.
This is one of the most important questions in metastatic kidney cancer.
Removing the primary kidney tumour in a patient with metastatic disease is called cytoreductive nephrectomy.
The purpose is to reduce the amount of cancer present in the body. However, removing the kidney is a major operation and does not remove metastatic disease elsewhere.
Therefore, the potential benefit must be weighed against:
Cytoreductive nephrectomy is therefore not a routine operation for every patient with Stage IV kidney cancer.
The role of surgery is individualized. Current evidence and ongoing clinical trials continue to examine which patients benefit from adding nephrectomy to modern systemic treatment.
Surgery may be considered in selected patients when the overall clinical situation suggests that removing the primary tumour could provide meaningful benefit.
Factors that may support consideration include:
A patient with a kidney tumour and only a small number of distant metastases may be considered differently from someone with extensive disease in multiple organs.
A major cancer operation is more likely to be considered when the patient is physically fit enough to tolerate it.
The behaviour of the cancer and its response to treatment are important when deciding whether surgery is appropriate.
In some patients, systemic treatment may be given first.
If the metastatic disease responds or remains controlled, the treatment team may reconsider the role of surgery.
The kidney tumour itself may cause:
In selected patients, local treatment of the kidney tumour may help control these symptoms.
If metastatic disease is limited and potentially treatable with surgery, radiation or another local treatment, surgery may become part of a broader treatment strategy.
There is no single answer for every patient.
Traditionally, selected patients underwent cytoreductive nephrectomy followed by systemic treatment.
However, modern systemic therapies have changed the treatment landscape.
In some patients, it may be appropriate to:
Start systemic treatment → assess response → reconsider surgery
This approach can provide additional information about how the cancer behaves before undertaking a major operation.
In other selected situations, surgery may still be considered earlier.
The sequence should therefore be decided by the multidisciplinary cancer team rather than by the presence of metastatic disease alone.
This situation is sometimes described as oligometastatic disease.
For example, a patient may have:
In selected patients, local treatment of metastatic disease may be considered.
Depending on the location, this may involve:
The decision depends on whether meaningful control of the known disease can realistically be achieved and whether the treatment risk is justified.
Selected patients with limited metastatic disease may therefore undergo treatment directed at both the kidney tumour and metastatic sites.
Metastatic disease does not always appear at the time of the original kidney cancer diagnosis.
A patient may undergo kidney cancer surgery and remain disease-free for years before developing a new metastatic lesion.
This is called metachronous recurrence.
A long disease-free interval can be an important part of the decision-making process.
Selected videos, patient stories and anonymised case summaries from Dr Swati Shah’s kidney cancer practice, chosen for metastatic kidney cancer and shared for patient education. Every patient’s plan is individual, and a past case or patient experience does not predict or guarantee an individual result.
Why partial nephrectomy can be preferred to radical nephrectomy in selected patients: the tumour is removed and normal kidney, with its function, is kept.
Kidney tumour: save the kidney or remove it? The choice depends on tumour size and position, its relation to blood vessels and the collecting system, kidney function and overall health.
Partial versus radical nephrectomy for a kidney tumour: when the kidney can be preserved and when it cannot (Hindi, with English title).
A patient from Ahmedabad describes cytoreductive surgery for a very large renal mass (PEComa, 17 to 18 cm) that had caused severe pain.
What to do when a kidney lump comes back: a patient describes robotic nephrectomy for a recurrent renal mass (Hindi).
A patient describes robotic radical nephrectomy for recurrent kidney cancer.
“My relative recently underwent robotic surgery for kidney cancer under the care of Dr. Swati Shah, and the experience was exceptional. Dr. Swati’s precision, confidence, and calm approach made a huge difference. She explained everything clearly, guided us at every step, and handled the surgery with outstanding skill. The robotic technique meant smaller cuts, less pain, and a much faster recovery than we expected.”
Paresh Undhad · Google review
“We really thank you dr swati. My wife staffing kidney problems but when we meet dr swati she faces woender full advice for surgey an after that my surgery successful . We really thank you so much.”
Sanjay Maniya · Google review
“I am impressed with the way Dr Swati treated my friend who had kidney tumour. She is extremely professional and takes time to listen and explain. My friend came from Rajasthan, underwent robotic surgery and went back in few days. I highly recommend her, if someone is looking for kidney cancer specialist in Gujarat”
Neha Jain · Google review
A 60-year-old man with urinary symptoms had a bulky, centrally necrotic right renal tumour abutting the liver, with multiple bony metastases. A right radical nephrectomy was performed with en bloc removal of the kidney, perinephric fat and right adrenal gland, with the aim of removing the primary tumour so that he could continue his oncological therapy. He recovered without complications and went home stable.
A 59-year-old man had a necrotic left renal mass invading the renal sinus, with a separate metastasis in the right adrenal gland. Robotic left radical nephrectomy with right adrenalectomy and retroperitoneal lymph node dissection was performed with blood loss of about 200 ml. Histopathology showed clear cell renal cell carcinoma with negative surgical margins and 17 lymph nodes free of tumour.
What these cases show: in metastatic renal cell carcinoma, the decision on cytoreductive nephrectomy or removal of a solitary or oligometastatic deposit depends on the burden and sites of metastasis, the IMDC risk group, the response to systemic therapy (immune checkpoint inhibitors and VEGF-targeted drugs) and the patient’s fitness. It is planned together with the medical oncologist, and the surgical aim is a safe operation with negative margins and complete removal of the primary tumour.
Details are anonymised and shown for education only.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
